Key facts
- This page summarizes Phoenix Venture Partners LP's Form 3 filing for Comera Life Sciences Holdings, Inc..
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 31 May 2022, 16:54.
Phoenix Venture Partners LP - 19 May 2022 Form 3 Insider Report for Comera Life Sciences Holdings, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 19 May 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Zachariah Jonasson, Managing Member of sole general partner on behalf of Phoenix Venture Partners LP
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Phoenix Venture Partners LP filed Form 3 for Comera Life Sciences Holdings, Inc. on 31 May 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CMRA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,052,835
- Date
- 19 May 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CMRA
holding
Derivative
Earn-Out Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 19 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 778,001
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
These shares were issued in exchange for the Reporting Person's holdings in Comera Life Sciences, Inc. (the "Company") pursuant to the Business Combination Agreement dated January 31, 2022 among the Issuer, the Company, OTR Acqusition Corp., CLS Sub Merger 1 Corp. and CLS Sub Merger 2 Corp.
Footnote F2
The shares reported are directly held by Phoenix Venture Partners LP (the "Fund"). Phoenix General Partner LLC is the sole general partner of the Fund and has sole authority to vote (or direct the vote of), and to dispose (or direct the disposal) of, these shares on behalf of the Fund. The Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.
Footnote F3
Each earn-out share represents a contingent right to receive one share of the Issuer's common stock if, at any time before May 19, 2024, the VWAP of the Issuer's common stock is equal to or greater than $12.50 for 20 trading days within any period of 30 consecutive trading days.